Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan

BACKGROUND: Recent data suggest that circulating endothelial and progenitor cells (CECs and CEPs, respectively) may have predictive potential in cancer patients treated with bevacizumab, the antibody recognizing vascular endothelial growth factor (VEGF). Here we report on CECs and CEPs investigated...

Descripción completa

Detalles Bibliográficos
Autores principales: Cuppini, Lucia, Calleri, Angelica, Bruzzone, Maria Grazia, Prodi, Elena, Anghileri, Elena, Pellegatta, Serena, Mancuso, Patrizia, Porrati, Paola, Di Stefano, Anna Luisa, Ceroni, Mauro, Bertolini, Francesco, Finocchiaro, Gaetano, Eoli, Marica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3772091/
https://www.ncbi.nlm.nih.gov/pubmed/24069296
http://dx.doi.org/10.1371/journal.pone.0074345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3772091/
https://www.ncbi.nlm.nih.gov/pubmed/24069296
http://dx.doi.org/10.1371/journal.pone.0074345

Ejemplares similares